• The CRTC-CREB Axis and Proteotoxic Stress: Insights from MLN

  2026-05-16

  This study uncovers how proteasome inhibitors, including MLN2238, activate the CRTC-CREB transcriptional axis to defend against proteotoxic and oxidative stress in Drosophila. The mechanistic link to ROS/JNK signaling reveals new avenues for investigating protein aggregation diseases and supports translational research targeting proteostasis and stress-responsive pathways.

• Methicillin Sodium Salt (C3238): Reliable Assays for S. aure

  2026-05-15

  This scenario-driven article addresses real-world challenges in Staphylococcus aureus infection research, focusing on experimental reliability and data interpretation. Using Methicillin sodium salt (SKU C3238) from APExBIO, we explore best practices for assay design, resistance profiling, and vendor selection. The article provides evidence-based guidance and protocol parameters to optimize reproducibility and sensitivity in cell-based and microbiological workflows.

• Faropenem Sodium: Applied Protocols for Penem Antibiotic Res

  2026-05-15

  Faropenem sodium stands out for its broad-spectrum activity and β-lactamase stability, making it a premier choice for complex Gram-positive, Gram-negative, and anaerobic infection models. This article details actionable workflows, advanced troubleshooting, and evidence-driven insights to maximize reproducibility and translational value in experimental antibiotic research.

• CircRHOBTB3 Suppresses Prostate Cancer via NONO-MAOA Pathway

  2026-05-14

  This study identifies circRHOBTB3 as a tumor suppressor in prostate cancer, demonstrating that it inhibits proliferation and metastasis by sequestering NONO and downregulating MAOA. The findings highlight a novel regulatory axis with implications for biomarker discovery and targeted therapies in metastatic prostate cancer.

• Bile Acid Subtypes & HyperScript III: Precision in CRC qPCR

  2026-05-14

  This thought-leadership article explores how advances in bile acid metabolism subtyping and next-generation reverse transcription chemistry—specifically APExBIO's HyperScript™ III RT SuperMix for qPCR (with gDNA wiper)—are transforming translational workflows in colorectal cancer (CRC) research. By integrating mechanistic insights, recent discoveries on immune-related gene markers (CLCA1, UGT2A3, ZG16), and evidence-based workflow recommendations, it provides strategic guidance to translational researchers seeking to bridge the gap from molecular discovery to clinical impact.

• Imipramine in Lipid Metabolism and Autophagy: A Research Fro

  2026-05-13

  Explore how Imipramine, a tricyclic antidepressant, uniquely interfaces with cellular lipid metabolism, autophagy, and apoptosis. This in-depth analysis connects recent lipidomics breakthroughs to practical assay design, offering nuanced guidance for advanced glioma, leukemia, and neuroimmunology research.

• Scenario-Driven Solutions with Verteporfin (SKU A8327) in Ce

  2026-05-13

  This article provides evidence-based, scenario-driven guidance for deploying Verteporfin (SKU A8327) in cell viability, proliferation, and cytotoxicity assays. By addressing common laboratory challenges with data-backed answers, it demonstrates how Verteporfin delivers reliable results and workflow confidence for biomedical researchers.

• Omeprazole (A2845): Technical Guidance for Gastric Acid Rese

  2026-05-12

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor designed for reproducible inhibition of gastric acid secretion in in vitro and ex vivo research settings. Researchers should not use this compound for diagnostic or clinical purposes; its validated utility is limited to mechanistic and pharmacological studies of gastric acid-related disorders.

• Birinapant (TL32711): Optimized Workflows for Apoptosis Indu

  2026-05-12

  Birinapant (TL32711) is redefining apoptosis research by enabling robust, quantifiable activation of cell death pathways in resistant cancer cell models. This guide delivers actionable protocol enhancements, troubleshooting strategies, and translational insight—bridging new biomarker findings to practical laboratory workflows.

• Precision Cytotoxicity: Live-Dead Cell Staining Kit I in Mec

  2026-05-11

  Explore how the Live-Dead Cell Staining Kit I (Calcein AM/PI) empowers advanced mammalian cell viability assays and mechanistic studies of cell death, including ferroptosis in TNBC. This in-depth analysis uniquely connects probe chemistry, workflow design, and translational oncology.

• SN-38 Inhibits FUBP1–FUSE Binding: Mechanistic Advances in C

  2026-05-11

  This article examines new evidence that 7-Ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan, disrupts the FUBP1–FUSE interaction, revealing a novel mechanism beyond topoisomerase I inhibition. These findings suggest expanded strategies for targeting transcriptional regulation and apoptosis in advanced cancer models, notably hepatocellular and colon carcinomas.

• Targeting UBE2F-CRL5 Axis for Apoptosis and Radiosensitizati

  2026-05-10

  Xu et al. present HA-9104, a first-in-class small molecule that selectively inhibits the UBE2F-CRL5 neddylation axis, leading to apoptosis and enhanced radiosensitivity in lung cancer models. Their study refines our understanding of neddylation pathway inhibition and highlights new molecular targets for cancer therapy.

• Distinct Apoptotic Pathways in BMECs Induced by Candida krus

  2026-05-09

  This study uniquely demonstrates that the yeast and hypha forms of Candida krusei trigger apoptosis in bovine mammary epithelial cells (BMECs) via separate signaling pathways. By dissecting mitochondrial- and death receptor-mediated mechanisms, the research advances understanding of pathogen-induced mastitis and highlights critical MAPK pathway intersections.

• EAGLE-2/EAGLE-3: Gepotidacin vs. Nitrofurantoin in UTI Thera

  2026-05-09

  The EAGLE-2 and EAGLE-3 phase 3 trials evaluated gepotidacin, a novel triazaacenaphthylene antibiotic, against nitrofurantoin for uncomplicated urinary tract infection in women. Gepotidacin demonstrated non-inferiority and, in one trial, superiority, indicating its clinical potential in the context of rising antimicrobial resistance.

• Bismuth Subsalicylate: Applied GI Research Workflows & Insig

  2026-05-08

  Bismuth Subsalicylate (1,3,2λ2-benzodioxabismin-4-one) empowers gastrointestinal disorder research with reproducible performance and robust anti-inflammatory action. Discover optimized protocols, troubleshooting strategies, and actionable insights for translational and mechanistic GI studies.

421 records 16/29 page Previous Next First page 上5页 1617181920 下5页 Last page